ProCE Banner Activity

Phase II AVANOVA2: Niraparib + Bevacizumab vs Niraparib Alone in Platinum-Sensitive Recurrent Ovarian Cancer

Slideset Download
Conference Coverage
In patients with recurrent ovarian cancer, the chemotherapy-free combination of niraparib plus bevacizumab significantly improved PFS vs niraparib alone, regardless of HRD status or chemotherapy-free interval.

Released: June 07, 2019

Expiration: June 05, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro